Artiva Biotherapeutics (ARTV) Assets Average (2024 - 2026)

Artiva Biotherapeutics (ARTV) has 3 years of Assets Average data on file, last reported at $118.4 million in Q1 2026.

• Assets Average for Q1 2026 came in at $118.4 million, down 40.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.4 million (down 40.9% YoY), and the FY2025 annual result was $170.3 million, up 8.21% from the prior year.
• Assets Average retreated to $118.4 million in Q1 2026 per ARTV's latest filing, from $139.9 million in the prior quarter.
• Over five years, Assets Average peaked at $217.6 million in Q4 2024 and troughed at $118.4 million in Q1 2026.
• A 3-year average of $166.7 million and a median of $159.1 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2025 and 2026: Assets Average gained 5.55% in 2025, then tumbled 40.9% in 2026.
• A 3-year view of Assets Average shows it stood at $217.6 million in 2024, then sank by 35.7% to $139.9 million in 2025, then fell by 15.33% to $118.4 million in 2026.
• Business Quant data shows ARTV's Assets Average at $118.4 million in Q1 2026, $139.9 million in Q4 2025, and $159.1 million in Q3 2025.